Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Cash from Investing Activities: 2009-2025

Historic Cash from Investing Activities for Northwest Biotherapeutics (NWBO) over the last 13 years, with Sep 2025 value amounting to -$513,000.

  • Northwest Biotherapeutics' Cash from Investing Activities fell 191.48% to -$513,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$988,000, marking a year-over-year increase of 27.03%. This contributed to the annual value of -$1.0 million for FY2024, which is 70.50% up from last year.
  • Per Northwest Biotherapeutics' latest filing, its Cash from Investing Activities stood at -$513,000 for Q3 2025, which was down 68.75% from -$304,000 recorded in Q2 2025.
  • Northwest Biotherapeutics' 5-year Cash from Investing Activities high stood at -$58,000 for Q1 2022, and its period low was -$2.7 million during Q3 2021.
  • In the last 3 years, Northwest Biotherapeutics' Cash from Investing Activities had a median value of -$418,000 in 2023 and averaged -$487,364.
  • Per our database at Business Quant, Northwest Biotherapeutics' Cash from Investing Activities spiked by 89.74% in 2022 and then tumbled by 2,198.28% in 2023.
  • Quarterly analysis of 5 years shows Northwest Biotherapeutics' Cash from Investing Activities stood at -$1.6 million in 2021, then tumbled by 39.09% to -$2.2 million in 2022, then spiked by 80.65% to -$418,000 in 2023, then soared by 81.34% to -$78,000 in 2024, then crashed by 191.48% to -$513,000 in 2025.
  • Its last three reported values are -$513,000 in Q3 2025, -$304,000 for Q2 2025, and -$93,000 during Q1 2025.